Boston Scientific completed the acquisition of Symetis for $435m.

Boston Scientific, a manufacturer of medical devices, completed the acquisition of Symetis, a privately-held Swiss structural heart company focused on minimally-invasive transcatheter aortic valve implantation devices, for $435m. "Adding the ACURATE family of valve products to our structural heart portfolio presents us with the opportunity to provide two distinctly different but complementary TAVI platforms enabling implanting physicians and hospitals to treat the broadest range of patients and aortic valve anatomies. This valve offering, along with our left atrial appendage closure device, uniquely position us to advance structural heart solutions for patients while fueling continued growth for the company," Ian Meredith, Boston Scientific Executive Vice President and Global Chief Medical Officer.